Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | PARG | Q86W56 | 3/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661264 | 0.92 | HAVCR2 (0.34) | HAVCR2BDKRB2BRD4CYP1A2METAP2 | |
| SCHEMBL4628060 | 0.90 | HAVCR2 (0.33) | HAVCR2BDKRB2BRD4CYP1A2METAP2 | |
| Benzoylenurea SCHEMBL15948987 | 0.90 | KDM4E (0.34) | HAVCR2PDPK1BDKRB2BRD4CYP1A2 | |
| SCHEMBL1660973 | 0.89 | CCNK (0.37) | HAVCR2PARGADRA1A | |
| SCHEMBL1661316 | 0.87 | USP1 (0.32) | HAVCR2 | |
| SCHEMBL2597134 | 0.85 | HAVCR2 (0.33) | HAVCR2PDPK1 | |
| SCHEMBL1661230 | 0.85 | CYP1A2 (0.39) | HAVCR2BDKRB2BRD4CYP1A2METAP2 | |
| Selurampanel SCHEMBL1660562 | 0.85 | HAVCR2 (0.34) | HAVCR2BRD4CYP1A2METAP2IMPDH2 | |
| Selurampanel SCHEMBL30259242 | 0.85 | HAVCR2 (0.34) | HAVCR2BRD4CYP1A2METAP2IMPDH2 | |
| SCHEMBL1661254 | 0.84 | HAVCR2 (0.34) | HAVCR2BRD4CYP1A2METAP2PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468732-B1 | 1H-Quinazoline-2,4-diones | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | claimed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | claimed |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | ALLGEIER HANS (DE) | 2014-01-16 | — | — | US | claimed |
| EP-2585070-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2013-05-01 | — | — | EP | claimed |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | claimed |
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | NOVARTIS AG (CH) | 2013-04-11 | — | — | US | claimed |
| WO-2013036224-A1 | USE OF 1H-QUINAZOLINE- 2, 4 -DIONES FOR USE IN THE PREVENTION OR TREATMENT PHOTOSENSITIVE EPILEPSY | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | claimed |
| EP-2490691-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | Novartis AG (CH) | 2012-08-29 | — | — | EP | claimed |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| WO-2011161249-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | claimed |
| WO-2011048150-A1 | USE OF 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | claimed |
| EP-2468732-B1 | 1H-Quinazoline-2,4-diones | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| EP-2468732-B1 | 1H-Quinazoline-2,4-diones | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | JOHNS DONALD (US) | 2014-06-12 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| EP-1871749-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090346-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | HAVCR2 1866/4885PDPK1 447/4885BDKRB2 290/4885 |
| US-20130096145-A1 | Use of 1H-quinazoline-2,4-diones | GRM1, GRIK2, GRIK1 | HAVCR2 3857/4885PDPK1 570/4885BDKRB2 160/4885 |
| US-20140018376-A1 | Use of 1H-Quinazoline-2,4-Diones | GRIK1, GRIK2, GRIK4 | HAVCR2 751/4885PDPK1 497/4885BDKRB2 381/4885 |
| US-20140163050-A1 | Use of 1H-quinazoline-2,4-diones | GRIK2, GRIK1, GRIK4 | HAVCR2 1866/4885PDPK1 447/4885BDKRB2 290/4885 |
| US-20120122903-A1 | 1-H-QUINAZOLINE-2, 4-DIONES FOR USE IN THE TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | CLN6, GBA1, GBA2 | HAVCR2 3421/4885PDPK1 767/4885BDKRB2 676/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | HAVCR2 4615/4885PDPK1 643/4885BDKRB2 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.